According to a new study, the drug behind the new pills to treat COVID-19 is very effective against the Omicron variant of the virus in lab tests.
but, Lab test We have also shown that available antibody therapies (usually given intravenously in hospitals) are substantially less effective against Omicron than early variants of the virus.Several antibody It has completely lost its ability to neutralize Omicron at realistic doses.
If the antiviral drug is confirmed to be capable of fighting Omicron Human patient, Welcome news. Public health officials hope that pills will become an increasingly common treatment for COVID-19, reducing the severity of illness in patients at risk and reducing the burden of pandemics.
So far, pills continue to be in short supply during the current Omicron wave, which is breaking case records in the United States and other countries.
The findings support other studies showing that most available antibody treatments are less effective against Omicron.Pharmaceutical companies can design, test and manufacture new antibody drugs targeting Omicron Mutant To overcome the limitations of current therapies, but this process will take months.
“The bottom line is that there are steps to treat Omicron, which is good news,” said Yoshihiro Kawaoka, director of research at the University of Wisconsin-Madison and a virologist at the University of Wisconsin and the University of Tokyo. I am. “But this is all laboratory research. It’s not yet known if this will be converted to humans.”
Kawaoka, his UW-Madison, and a collaborator at the National Institute of Infectious Diseases in Tokyo announced their findings in the New England Journal of Medicine on January 26.
Clinically available pills and antibodies were designed and tested before researchers identified Omicron variants that were significantly different from previous versions of the virus.When Omicron was identified, scientists said these differences Viral genome, May reduce the effectiveness of drugs designed to treat the original version of the virus.
In a laboratory using non-human primate cells, Kawaoka’s team teamed up with a series of antibodies and anti-antibodies against the original strain of the COVID-19 virus and its prominent variants, including the alpha, delta, and omicron strains. I tested virus therapy.
Merck’s pilmornepyrabir and the intravenous drug remdesivir were as effective against the Omicron variant as they were against the early viral strains.
Instead of testing Pfizer’s Paxlovid pillDesigned to be taken orally, the team tested related drugs by intravenously administered Pfizer. The two drugs destroy the same part of the viral mechanism.Researchers have found that the form of intravenous administration is drag Retaining its effectiveness against Omicron, this version is now Clinical trials..
All four antibody treatments tested by the researchers were less effective against Omicron than against early strains of the virus. Two treatments, Sotrovimab with GlaxoSmithKline and Ebcheld with AstraZeneca, retained some ability to neutralize the virus. However, compared to previous versions, it required 3 to 100 times more medication to neutralize Omicron.AstraZeneca antibody is not approved for use in the United States
Two antibody treatments with Lily and Regenerone failed to neutralize Omicron at typical doses.
These findings are expected to consider how the Omicron variant differs from the previous SARS-CoV-2 strain, the COVID-19 virus. Omicron has dozens of mutations in the peplomer protein that the virus uses to invade and infect cells. Most antibodies are designed to bind to and neutralize the original peplomer protein, and major changes to the protein make it less likely that the antibody will attach to it.
In contrast, antiviral drugs target molecular mechanisms virus Used to make a copy of itself in the cell. Omicron variants make only minor changes to this mechanism, which increases the likelihood that the drug retains its ability to interfere with this replication process.
Kawaoka Lab is currently researching new antibody candidates to identify potential neutralizers. Omicron Mutant.
University of Wisconsin-Madison
Quote: Current anti-COVID pills work well against Omicron, but antibody drugs are less effective (January 26, 2022). omicron-antibody.html
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. Content is provided for informational purposes only.
Current anti-COVID pills work well against omicron, but antibody drugs are less effective Source link Current anti-COVID pills work well against omicron, but antibody drugs are less effective
The post Current anti-COVID pills work well against omicron, but antibody drugs are less effective appeared first on California News Times.